国际麻醉学与复苏杂志
國際痳醉學與複囌雜誌
국제마취학여복소잡지
INTERNATIONAL JOURNAL OF ANESTHESIOLOGY AND RESUSCITATION
2010年
4期
314-316
,共3页
谢辉兰%李明星%宋炯%段若望
謝輝蘭%李明星%宋炯%段若望
사휘란%리명성%송형%단약망
依托咪酯%血小板%活化标志物%肺癌
依託咪酯%血小闆%活化標誌物%肺癌
의탁미지%혈소판%활화표지물%폐암
Etomidate%Blood platelets%Activation marker%Lung cancer
目的 探讨依托咪酯对肺癌患者外周静脉血血小板活化标志物CD62p和CD41/61的影响.方法 40例肺癌患者随机分为4组(A组、B组、C组、D组)抽取外周静脉血,B组、C组和D组的血标本分别加入0.2、2、20 mg/L依托咪酯,抽取10名健康志愿者外周静脉血作为对照组(E组,n=10),E组和A组不加人药物.应用流式细胞仪测定血小板活化标志物CD62p和CD41/61的表达量.结果 5组患者的年龄、性别、体重,血小板计数和凝血时间差异均无统计学意义.与E组血小板活化标志物CD62p(3.3 ±1.9)%、CD41/61(93.1+3.4)%比较,A组血小板活化标志物CD62p(37.1±20.3)%、CD41/61(97.2±1.4)%表达增高(P<0.01);与A组血小板活化标志物比较,C组CD62p(20.9+9.2)%表达降低(RO.05),D组CD62p(17.9±15.6)%表达明显降低(P<0.01),C组、D组CD41/61无明显改变,B组血小板活化标志物无明显变化(P>0.05).结论 肺癌患者外周静脉血血小板活化标志物CD62p、CD41/61表达高于正常人,在体外依托咪酯2 mg,L和20 mg/L可以抑制CD62p表达,抑制血小板的活化.
目的 探討依託咪酯對肺癌患者外週靜脈血血小闆活化標誌物CD62p和CD41/61的影響.方法 40例肺癌患者隨機分為4組(A組、B組、C組、D組)抽取外週靜脈血,B組、C組和D組的血標本分彆加入0.2、2、20 mg/L依託咪酯,抽取10名健康誌願者外週靜脈血作為對照組(E組,n=10),E組和A組不加人藥物.應用流式細胞儀測定血小闆活化標誌物CD62p和CD41/61的錶達量.結果 5組患者的年齡、性彆、體重,血小闆計數和凝血時間差異均無統計學意義.與E組血小闆活化標誌物CD62p(3.3 ±1.9)%、CD41/61(93.1+3.4)%比較,A組血小闆活化標誌物CD62p(37.1±20.3)%、CD41/61(97.2±1.4)%錶達增高(P<0.01);與A組血小闆活化標誌物比較,C組CD62p(20.9+9.2)%錶達降低(RO.05),D組CD62p(17.9±15.6)%錶達明顯降低(P<0.01),C組、D組CD41/61無明顯改變,B組血小闆活化標誌物無明顯變化(P>0.05).結論 肺癌患者外週靜脈血血小闆活化標誌物CD62p、CD41/61錶達高于正常人,在體外依託咪酯2 mg,L和20 mg/L可以抑製CD62p錶達,抑製血小闆的活化.
목적 탐토의탁미지대폐암환자외주정맥혈혈소판활화표지물CD62p화CD41/61적영향.방법 40례폐암환자수궤분위4조(A조、B조、C조、D조)추취외주정맥혈,B조、C조화D조적혈표본분별가입0.2、2、20 mg/L의탁미지,추취10명건강지원자외주정맥혈작위대조조(E조,n=10),E조화A조불가인약물.응용류식세포의측정혈소판활화표지물CD62p화CD41/61적표체량.결과 5조환자적년령、성별、체중,혈소판계수화응혈시간차이균무통계학의의.여E조혈소판활화표지물CD62p(3.3 ±1.9)%、CD41/61(93.1+3.4)%비교,A조혈소판활화표지물CD62p(37.1±20.3)%、CD41/61(97.2±1.4)%표체증고(P<0.01);여A조혈소판활화표지물비교,C조CD62p(20.9+9.2)%표체강저(RO.05),D조CD62p(17.9±15.6)%표체명현강저(P<0.01),C조、D조CD41/61무명현개변,B조혈소판활화표지물무명현변화(P>0.05).결론 폐암환자외주정맥혈혈소판활화표지물CD62p、CD41/61표체고우정상인,재체외의탁미지2 mg,L화20 mg/L가이억제CD62p표체,억제혈소판적활화.
Objective To investigate the effect of etomidate on the expression of activation makers of platelet CD62p and CD41/ 61 in peripheral venous blood in patients with lung cancer. Methods Peripheral venous blood samples were taken from 10 healthy volunteers (group E) and 40 patients with lung cancer. The 40 patients with lung cancer were randomly divided into 4 groups (n=10 each): groups A, B, C and D. The blood samples in groups E and A were incubated without etomidate, while the blood samples in groups B, C and D were incubated with etomidate 0.2, 2 and 20 mg/L, respectively. The inhibitory effects of etomidate on expression of activation makers of platelet CD62p and CD41/61 were determined by flow cytometry. Results The five groups were comparable with respect to age, body weight, platelet count and coagulation time. The expression of C D62p (37.1±20.3) %、 CD41/61 (97.2±1.4) % on the platelet surface was significantly increased in patients with lung cancer than the expression of CD62p (3.3±1.9)%, CD41/61 (93.1±3.4)% in healthy adults (P<0.01).Compare with group A, the expression of activation makers of platelet CD62p (20.9±9.2)%on the platelet surface in group C was decreased (P<0.05)and the expression of activation makers of platelet CD62p (17.9±15.6)% in group D was significantly decreased(P<0.01),whereas etomidate 0.2 mg/L had no significantly effect on CD62p and CD41/61. Conclusion The expression of activation makers of plateleta significantly increased in patients with lung cancer compared with healthy adults. In vitro,etomidate 2 and 20 mg/L can inhibit the expression of CD62p.
